Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.53 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.53 |
| ▸ | ITGAV | P06756 | 1/20 | 0.53 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.53 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.53 |
| ▸ | CFD | P00746 | 16/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16099454 | 1.00 | ITGB3 (0.53) | ITGB3ITGB1ITGAVITGA5ITGA4 | |
| SCHEMBL16098966 | 0.85 | ITGB3 (0.56) | ITGB3ITGB1ITGAVITGA5ITGA4 | |
| SCHEMBL16098968 | 0.85 | ITGB3 (0.56) | ITGB3ITGB1ITGAVITGA5ITGA4 | |
| SCHEMBL16098953 | 0.83 | KMT2A (0.61) | ITGB3ITGB1ITGAVITGA5ITGA4 | |
| SCHEMBL16098951 | 0.83 | KMT2A (0.61) | ITGB3ITGB1ITGAVITGA5ITGA4 | |
| SCHEMBL16099000 | 0.81 | ITGB3 (0.59) | ITGB3ITGB1ITGAVITGA5ITGA4 | |
| SCHEMBL16098997 | 0.81 | ITGB3 (0.59) | ITGB3ITGB1ITGAVITGA5ITGA4 | |
| SCHEMBL16099157 | 0.81 | ITGB3 (0.58) | ITGB3ITGB1ITGAVITGA5ITGA4 | |
| SCHEMBL16099158 | 0.81 | ITGB3 (0.58) | ITGB3ITGB1ITGAVITGA5ITGA4 | |
| SCHEMBL31710264 | 0.80 | KMT2A (0.69) | ITGB3ITGB1ITGAVITGA5ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708340-B2 | Urea derivatives and their use as fatty-acid binding protein (FABP) inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2017-07-18 | — | — | US | claimed |
| US-20160185795-A1 | UREA DERIVATIVES AND THEIR USE AS FATTY-ACID BINDING PROTEIN (FABP) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2016-06-30 | — | — | US | claimed |
| WO-2014146994-A1 | UREA DERIVATIVES AND THEIR USE AS FATTY-ACID BINDING PROTEIN (FABP) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-25 | — | — | WO | claimed |
| US-9708340-B2 | Urea derivatives and their use as fatty-acid binding protein (FABP) inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708340-B2 | Urea derivatives and their use as fatty-acid binding protein (FABP) inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708340-B2 | Urea derivatives and their use as fatty-acid binding protein (FABP) inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160185795-A1 | UREA DERIVATIVES AND THEIR USE AS FATTY-ACID BINDING PROTEIN (FABP) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160185795-A1 | UREA DERIVATIVES AND THEIR USE AS FATTY-ACID BINDING PROTEIN (FABP) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160185795-A1 | UREA DERIVATIVES AND THEIR USE AS FATTY-ACID BINDING PROTEIN (FABP) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2016-06-30 | — | — | US | disclosed |
| WO-2014146994-A1 | UREA DERIVATIVES AND THEIR USE AS FATTY-ACID BINDING PROTEIN (FABP) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014146994-A1 | UREA DERIVATIVES AND THEIR USE AS FATTY-ACID BINDING PROTEIN (FABP) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185795-A1 | UREA DERIVATIVES AND THEIR USE AS FATTY-ACID BINDING PROTEIN (FABP) INHIBITORS | FABP1, FABP5, FABP2 | ITGB3 4019/4885ITGB1 4032/4885ITGAV 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.